Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Sarilumab (L04Ac14) As Part Of A So-Called Open House Model.

AOK Rhineland-Palatinate Saarland - The health insurance fund Germany has Released a tender for Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Sarilumab (L04Ac14) As Part Of A So-Called Open House Model. in Pharmaceuticals. The tender was released on Oct 10, 2023.

Country - Germany

Summary - Conclusion Of Non-Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8/130C Paragraph 1 Sgb V For Drugs With The Active Ingredient Sarilumab (L04Ac14) As Part Of A So-Called Open House Model.

Deadline - Sep 30, 2025

GT reference number - 72908591

Product classification - Pharmaceutical products